GHRP-2 Dosage Guide: How Much, How Often, and Common Mistakes

GHRP-2 at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

The wrong GHRP-2 dose — too high, too low, or escalated too quickly — is the most common reason people stop the drug. FDA-approved agents have specific labeled dosing.

Standard Dosing Schedule for GHRP-2

FDA-approved agents have specific labeled dosing. Research-only GHS peptides have no validated human dosing.

The typical schedule for GHRP-2 is once daily to once weekly depending on agent via subcutaneous injection (peptides) or oral (small molecules). Half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for GHRP-2 holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of GHRP-2 is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in GHRP-2 side effects and the cost angle of dose escalation in GHRP-2 cost.

What the Trials Used

Published trial data for GHRP-2 comes primarily from: Stanley 2010 (tesamorelin in HIV-lipodystrophy); Nass 2008 (MK-677 in older adults).

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For GHRP-2: the standard contraindications for this drug class apply.

Bottom Line

Most GHRP-2 dose questions resolve in a 5-minute conversation with a clinician. Don't carry them around — get them answered.

Frequently Asked Questions

Related Reading

• GHRP-2: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• GHRP-2 Side Effects in 2026: Real Reports, Real Solutions
• Real GHRP-2 Results: What 6 and 12 Months Actually Look Like
• GHRP-2 Cost in 2026: What You'll Actually Pay (Real Numbers)
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.